Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

November 30, 2017November 30, 2017

Mothers Exposed to Antibiotics Increase the Risk of IBD in Offspring, Mouse Study Shows

News

Mothers exposed to antibiotics during pregnancy may increase their child’s risk of inflammatory bowel disease (IBD) later in life, said researchers at New York’s NYU Langone Health. Their study, “Intergenerational transfer of ... Read more

November 28, 2017November 28, 2017

Combining Thiopurine and Anti-TNF Agents Increases Lymphoma Risk in Adults, Study Finds

News

Adult patients with inflammatory bowel disease (IBD) who receive thiopurine monotherapy or anti–tumor necrosis factor (TNF) monotherapy have a higher risk of developing lymphoma when compared to untreated patients, a ... Read more

November 17, 2017November 17, 2017

First RNA-Based Blood Test Available for IBS, IBD Diagnoses, IQuity Announces

News

IQuity, a leading life science technology company in the field of RNA-based diagnosis, announced the release of IsolateIBS-IBD, a pioneering blood test that helps clinicians identify with great accuracy irritable bowel ... Read more

November 14, 2017November 14, 2017

Strict Dietary Changes Help IBD Patients Achieve Clinical Remission in Small Study

News

Researchers have found that eliminating foods known to stimulate intestinal inflammation — a dietary approach known as the autoimmune protocol diet — improves clinical outcomes in inflammatory bowel disease (IBD) ... Read more

November 8, 2017November 8, 2017

RedHill Offers Data Showing EnteraGam’s Benefits as Dietary Therapy for IBD Patients

News

RedHill Biopharma says its medical food, EnteraGam, is clinically and economically beneficial for inflammatory bowel disease (IBD) patients with chronic diarrhea. The Israeli company presented EnteraGam on Nov. 7 at the International Society ... Read more

November 1, 2017

Effectiveness, Safety of Remicade’s Biosimilar, Inflectra, Confirmed in Phase 3 Trial

News

Switching Crohn’s disease patients from Remicade (infliximab) to its biosimilar Inflectra has no negative impact to treatment safety or effectiveness, a Phase 3 clinical trial shows. Pfizer and Celltrion Healthcare jointly presented those ... Read more

October 27, 2017October 27, 2017

Innovation Readies Next Clinical Phase for Investigational IBD Therapy Brilacidin

News

Innovation Pharmaceuticals, a clinical-stage biopharmaceutical company, issued an update on its research program for Brilacidin, an investigational non-corticosteroid and anti-inflammatory therapy for inflammatory bowel disease (IBD). The company is planning ... Read more

October 20, 2017October 20, 2017

Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show

News

Celgene recently presented positive data from two Phase 2 studies — the STEPSTONE and TOUCHSTONE studies — for the company’s investigational compound ozanimod (RPC-1063) as a therapy for Crohn’s disease and ulcerative colitis ... Read more

October 18, 2017

Entyvio Eased Early Symptoms of Ulcerative Colitis and Crohn’s, New Analysis Shows

News

Entyvio (vedolizumab) alleviated some of the early symptoms of patients with moderate to severe ulcerative colitis and Crohn’s disease, a new analysis of Phase 3 trial results indicates. Takeda Pharmaceutical presented the ... Read more

October 17, 2017

Rectal Therapy with Prograf Helped Patients with Resistant UC, Study Shows

News

Patients with resistant ulcerative proctitis, a mild form of ulcerative colitis (UC), respond to therapy with rectal Prograf (tacrolimus) ointment, achieving clinical remission and mucosal healing, according to the results of ... Read more